The global doxorubicin market, valued at USD 1.35 billion in 2024, is projected to expand steadily and reach USD 2.56 billion by 2035, driven by a CAGR of 5.98% between 2025 and 2035. This growth is fueled by a rising global cancer burden, broader adoption of chemotherapy regimens, and increasing development of safer, next-generation doxorubicin […]








